Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript
Summarize this article with:
SA Transcripts157.31K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions December 11, 2025 11:00 AM EST Company Participants Jan van de Winkel - Co-Founder, President & CEOTahamtan Ahmadi - Executive VP, Chief Medical Officer & Head of Experimental MedicinesJudith Klimovsky - Executive VP & Chief Development Officer Conference Call Participants Lorenzo FalchiJonathan Chang - Leerink Partners LLC, Research DivisionMatthew Phipps - William Blair & Company L.L.C., Research DivisionJudah Frommer - Morgan Stanley, Research DivisionJaena Han - TD Cowen, Research DivisionQize Ding - Rothschild & Co Redburn, Research DivisionAsthika Goonewardene - Truist Securities, Inc., Research Division Presentation Operator Hello, and welcome to Genmab's ASH 2025 update. As a reminder, this webcast is being recorded. During this webcast, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. Genmab is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results, unless it is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab moving forward. Please refer our website for more information on Genmab and privacy policy, I would now like to hand over to your first speaker today, Jan Van de Winkel. Please go ahead. Jan van de WinkelCo-Founder, President & CEO Hello, and welcome to Genmab's 2025 R&D update and ASH data review. I'm Jan Van de Winkel, President and CEO of Genmab. I'm delighted to share with you some of the highlights for Genmab in 2025 as well as exciting EPKINLY data from this year's ASH meeting.
Recommended For You